6,062
Views
10
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States

ORCID Icon, , , ORCID Icon, , , , ORCID Icon, , , & show all
Pages 469-480 | Received 13 Jan 2022, Accepted 15 Feb 2022, Published online: 05 Apr 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.